GlassScriptPhysician profile
Lowrey Pearson King
NPI 1962446427
$821.45
in general payments reported to CMS, 2019-2025
14 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $6.91 · 2022: $58.33 · 2023: $121 · 2024: $91.51 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $245.61 | 2019 | |
| Astellas Pharma US INC | $145.86 | 2024-2025 | Izervay |
| Dutch Ophthalmic, USA | $78.73 | 2023-2024 | Eva, Combined Machine, Tissueblue |
| Alimera Sciences, INC. | $66.29 | 2019-2022 | |
| Coherus Oncology, INC. | $56.78 | 2023 | |
| Genentech USA, INC. | $39.27 | 2022-2023 | Vabysmo |
| Lensar, INC. | $33.88 | 2025 | Lensar Laser System |
| Glaukos Corporation | $31.05 | 2025 | Istent Infinite, Idosetr |
| Harrow Eye, LLC | $27.07 | 2025 | Iheezo |
| Novartis Pharmaceuticals Corporation | $25.69 | 2019 | |
| Abbvie INC. | $21.92 | 2019 | |
| Notal Vision, INC. | $18.05 | 2024 | Foresee Home |
| Rayner Intraocular Lenses Limited | $16.46 | 2023 | Rayone Aspheric, Rayone Emv, Omidria |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowrey King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.